19 June 2023 - Ibrutinib (Imbruvica) 140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment of patients with mantle cell lymphoma that does not respond satisfactorily to rituximab-based chemotherapy or for other reasons are not considered suitable for treatment with chemoimmunotherapy.

Imbruvica 560 mg tablets have previously been included in the drug benefits only for the treatment of patients with mantle cell lymphoma that does not respond satisfactorily to rituximab-based chemotherapy or for other reasons are not considered suitable for treatment with chemoimmunotherapy.

Read TLV News [Swedish]